No doubt 2025 will usher in many more advances in CRISPR therapies, thanks to the FDA’s new Platform Technology Designation ...

Experts agree that advances to GMO technology means laws need to change. But just how those changes look is contentious.

USDA Animal and Plant Health Inspection Service (APHIS) announced on January 23, 2025, that it is reinstating its legacy ...

Casgevy (exagamglogene autotemcel or exa-cel) became the first drug based on the CRISPR/Cas9 gene-editing technology ... application of the technology, meaning that bone marrow stem cells are ...

CRISPR Therapeutics (NASDAQ:CRSP – Free Report) had its target price decreased by Citigroup from $89.00 to $82.00 in a report ...

Gene editing techniques may eventually allow trisomy to be treated at the cellular level, according to an in vitro ...

Crispr Therapeutics AG has revenue declines but holds strong financials. Promising Sickle Cell therapy & 2025 data readouts ...

The CRISPR-Cas9 system offers groundbreaking genome editing capabilities, yet off-target cleavage raises concerns about ...

The consensus price target for CRISPR Therapeutics AG (NASDAQ:CRSP) has been adjusted from $72.75 to $65, reflecting changes in financial performance and industry developments. Despite a quarterly ...

By Balambal Suryanarayanan CRISPR-Cas9 is a repurposed gene editing tool that allows scientists to cut, replace, and insert pieces of DNA in precise regions along the strand. Courtesy of NIH Image ...